# Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients

> **NCT00655135** · PHASE2 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 185 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** LDP-02
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00655135
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-02
- **Primary completion:** 2002-06
- **Final completion:** —
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2008-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00655135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00655135, "Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00655135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*